Rena Conti, Ph.D., is the associate research director of biopharma & public policy for the Boston University Institute for Health System Innovation & Policy. She is also an Associate Professor at the Boston University Questrom School of Business, Department of Markets, Public Policy and Law. From 2006 through June 2018, Professor Conti was an Associate Professor of Health Economics and Policy at the University of Chicago. Dr. Conti is a health economist. Her research focuses on the organization, financing and regulation of medical care. She has written extensively on the pricing, demand and supply of prescription drugs.
Thomas J. Cosgrove, J.D., M.A., is a partner in Covington’s Food, Drug and Device Practice Group. He joined Covington in 2017 from the Food and Drug Administration (FDA), where he was a senior official charged with ensuring the quality of drugs and therapeutic biologics marketed to U.S. patients. Mr. Cosgrove brings a wealth of experience to bear in helping clients navigate the complex world of pharmaceutical compliance and enforcement in the United States and around the globe. At FDA, Mr. Cosgrove held senior leadership positions within the Office of Compliance in the Center for Drug Evaluation and Research (CDER), including leading the organization as Acting Director in 2016. Beginning in 2014, he led the Office of Manufacturing Quality (OMQ), where he was responsible for CDER’s enforcement activities covering current good manufacturing practice (CGMP) and drug quality. In this role, Mr. Cosgrove was responsible for setting FDA’s CGMP enforcement priorities and for clearing warning letters, import alerts, and referrals for civil and criminal enforcement. He also played a central role in the FDA’s deliberations concerning the approval of marketing applications submitted by companies with manufacturing compliance challenges. As Acting Director of CDER Compliance in 2016, Mr. Cosgrove oversaw OMQ as well as the offices responsible for enforcing FDA’s requirements for drug approval and labeling, human drug compounding, drug supply chain security and integrity, and clinical trials and bioequivalence studies. He is a frequent speaker at conferences and trainings focused on drug quality, compliance, and enforcement at home and abroad.
Erin Fox, Pharm.D., BCPS, FASHP., is senior director of drug information and support services at University of Utah Health. Dr. Fox is also associate professor (adjunct), at the Department of Pharmacotherapy, University of Utah College of Pharmacy. The University of Utah Drug Information Service provides content for the ASHP Drug Shortage Resource Center and Dr. Fox serves as a media resource and advocate for changes to improve the ongoing drug shortage situation and rising drug costs. Dr. Fox is recognized as an expert in drug shortages and has received the ISMP Cheers Award and ASHP Award of Excellence in recognition for her work on drug shortages.
Nicolette Louissaint, Ph.D., is the executive director of Healthcare Ready where she works to meet the most pressing patient needs before, during and after natural disasters, disease outbreaks and catastrophic events. Healthcare Ready coordinates with health and emergency management across the public and private sectors to ensure communities are prepared and able to bounce back following disasters. Prior to joining Healthcare Ready, Dr. Louissaint was the Senior Advisor to the State Department’s Special Coordinator for Ebola during the height of the Ebola Epidemic of 2014. In this role, she helped coordinate international response efforts. Dr. Louissaint currently serves as the Public Health Representative on FEMA’s National Advisory Council and as a Commissioner on the Baltimore City Sustainability Commission. Additionally, she serves as a co-chair of the Healthcare and Public Health Sector Coordinating Council (HPHSCC), leading on supply chain issues. In this role she also manages the Medical Materials Coordination Group within the HPHSCC. Dr. Louissaint holds Bachelor of Science degrees in chemical engineering and biological sciences from Carnegie Mellon University, and a Ph.D. in pharmacology and molecular sciences from Johns Hopkins University School of Medicine. She completed post-doctoral fellowships at the Johns Hopkins University and the American Association for the Advancement of Science.
Sarah J. Dash, MPH, is the president and chief executive officer at the Alliance for Health Policy. She drives the mission and vision of the Alliance, as well as advances and maintains the reputation of the organization as the leading nonpartisan resource for policymakers and health leaders in an evolving health policy environment. Sarah joined the Alliance in 2014 as the vice president for policy and became president and CEO in May 2017. Sarah has long been an influential force in shaping health policy, having served as a senior aide on Capitol Hill and as a member of the research faculty at the Georgetown University Health Policy Institute’s Center on Health Insurance Reforms. Sarah holds a master’s degree in public health from the Yale School of Public Health and a bachelor’s degree in chemistry and literature from MIT. Sarah also holds an Executive Certificate in Nonprofit Management from Georgetown University.